Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

L. Wang, Michael; Rule, S.; Martin, P.; Goy, A.; Auer, R.; Kahl, B.; Jurczak, W.; Advani, R.; Romaguera, J.; E. Williams, Michael; Barrientos, J.; Chmielowska, E.; Radford, J.; Stilgenbauer, S.; Dreyling, M.; Jędrzejczak, W.; W M Johnson, Peter; Spurgeon, S.; Li, Lei; Zhang, L.; Newberry, K.; Ou, Zhishuo; Cheng, N.; Fang, B.; Mcgreivy, J.; Clow, F.; Buggy, J.; Chang, B.; Beaupre, D.; Kunkel, L.; Blum, K.

doi:10.1056/NEJMoa1306220

Public

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

Shared by NobleBlocks on Jun 19, 2013 • 12:00 AM UTC

Authors:

Michael L. Wang

S. Rule

P. Martin

Abstract

BACKGROUND Bruton's tyrosine kinase (BTK) is a mediator of the B-cell–receptor signaling pathway implicated in the pathogenesis of B-cell cancers. In a phase 1 study, ibrutinib, a BTK inhibitor, showed antitumor activity in several types of non-Hodgkin's lymphoma, including mantle-cell lymphoma. MET...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!